Supplementary Table 1. Univariable logistic regression for prolonged length of stay

Variable	OR (95% CI)	*p*-value
Age (per 10 years)	1.16 (1.12–1.20)	<0.001
Sex, male	0.87 (0.79–0.96)	0.003
Initial NIHSS	1.12 (1.11–1.13)	<0.001
Hypertension	1.15 (1.04–1.27)	0.005
Diabetes mellitus	1.23 (1.12–1.35)	<0.001
Atrial fibrillation	1.68 (1.50–1.88)	<0.001
Previous stroke	1.60 (1.44–1.78)	<0.001
Coronary heart disease	1.58 (1.37–1.81)	<0.001
Current smoker	0.76 (0.67–0.85)	<0.001
Premorbid mRS	1.42 (1.36–1.48)	<0.001
Systolic BP (per 10 mmHg)	0.99 (0.97–1.00)	0.094
Diastolic BP (per 10 mmHg)	0.93 (0.91–0.96)	<0.001
Initial glucose (per 10 mg/dL)	1.02 (1.02–1.03)	<0.001
Total cholesterol (per 10 mg/dL)	0.97 (0.96–0.98)	<0.001
Triglycerides (per 10 mg/dL)	0.98 (0.98–0.99)	<0.001
HDL cholesterol (mg/dL)	1.00 (0.99–1.00)	0.009
LDL cholesterol (per 10 mg/dL)	0.98 (0.96–0.99)	<0.001
Hemoglobin (g/dL)	0.89 (0.87–0.91)	<0.001
Platelets (per 10 $\times 10^3/\mu L$)	0.99 (0.98–1.00)	<0.001
Creatinine (mg/dL)	1.14 (1.07–1.21)	<0.001
WBC ($\times 10^3/\mu L$)	1.11 (1.10–1.13)	<0.001
PT (INR)	2.05 (1.67–2.52)	<0.001
IV thrombolysis	1.54 (1.33–1.79)	<0.001
IA thrombectomy	2.46 (2.17–2.79)	<0.001
Relevant large artery steno-occlusion	1.82 (1.66–2.00)	<0.001
TOAST: LAA (vs. SVO)	2.74 (2.30–3.28)	<0.001
TOAST: CE (vs. SVO)	4.24 (3.51–5.12)	<0.001
TOAST: Other determined (vs. SVO)	3.75 (3.03–4.65)	<0.001
TOAST: Undetermined (vs. SVO)	2.61 (2.13–3.19)	<0.001

Univariable logistic regression was performed for each candidate variable using the full cohort (n=8,448). Odds ratios indicate the change in odds of prolonged length of stay (≥8 days) per unit increase or for the presence of a binary covariate.

OR, odds ratio; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; WBC, white blood cell count; PT, prothrombin time; INR, international normalized ratio; IV, intravenous; IA, intra-arterial; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, large artery atherosclerosis; SVO, small vessel occlusion; CE, cardioembolism.